만성 요통(CLBP) 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the chronic lower back pain market size in 2026 is estimated at USD 2.57 billion, growing from 2025 value of USD 2.38 billion with 2031 projections showing USD 3.76 billion, growing at 7.93% CAGR over 2026-2031.

This report is Segmented by Pain Type (Acute Pain, Sub-Acute Low Back Pain, Chronic Back Pain, Other Pain Types), Diagnosis (Assessment of Pain Scores, Clinical History, and More), Therapy Modality (Pharmacologic, and More), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Chronic Lower Back Pain (CLBP) Market Trends and Insights

Rapid Uptake of Neuromodulation & SCS Implants

Closed-loop spinal cord stimulation (SCS) has shifted the therapeutic paradigm by automatically adjusting signals in response to physiologic feedback, curbing overstimulation without clinician input. Medtronic's Inceptiv system showed 82% of recipients experienced at least 50% pain reduction at 12 months. Nevro's HFX AdaptivAI platform uses machine-learning algorithms to trim charging frequency while preserving efficacy. Together, these advances elevate long-term outcomes, improve health-related quality of life metrics, and reduce unplanned clinical visits. Reimbursement is increasingly tied to real-world evidence, and payers in the United States have begun adding supplemental payments for closed-loop stimulators that demonstrate opioid-sparing benefits. Manufacturers are also miniaturizing pulse generators, making same-day ambulatory implantation viable. Forward integration between device makers and telehealth platforms is creating an ecosystem where therapy parameters and patient-reported outcomes flow into cloud dashboards, enabling proactive adjustments by multidisciplinary teams.

Rising Prevalence of Obesity & Sedentary Lifestyles

Obesity induces biomechanical stress that accelerates intervertebral disc degeneration, heightening chronic lower back pain across demographics. Remote work adoption since 2020 has deepened sedentary behavior, with musculoskeletal complaints ranking among the top reasons for physician visits. Economically, the United States registered USD 725 billion in chronic pain-related costs during 2024, hammered by health expenditures and lost productivity. Cellular gerontology studies now link adipose-driven inflammation to senescent "zombie" cells in spinal discs, and early-stage combination drugs that target these senescent cells have shown disc-height preservation in preclinical models. Such findings are steering investment toward regenerative pharmacology that intersects metabolic and orthopedic pathways.

High Upfront Cost of Advanced Neurostimulators

Implantation of closed-loop SCS systems carries procedure costs between USD 35,000 and USD 70,000, posing reimbursement hurdles in low-resource settings. Revision surgeries occur in 9.82% of implanted patients, often for lead migration or inadequate pain control, compounding total lifetime expense. Cost-utility studies, however, prove rechargeable units deliver USD 104,000-168,833 in lifetime savings relative to non-rechargeable generators by minimizing battery replacements. Manufacturers are responding with simplified electrode arrays that shorten operating-room time and hospital stays, nudging health-economic equations in their favor.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Geriatric Population Susceptible to CLBP
2. Expansion of Stem-Cell & Orthobiologic Trials
3. Strict Opioid Prescribing & Reimbursement Clamp-Downs

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Chronic manifestations held 47.35% of the chronic lower back pain market share in 2025, underscoring the need for long-term multidisciplinary care. Acute pain, though smaller, will expand at a 9.02% CAGR by 2031 as surgical volumes climb and hospitals standardize enhanced-recovery protocols. Acute management is benefiting from the FDA approval of suzetrigine, the first new non-opioid molecule in decades, enabling multimodal analgesia that limits narcotic use. Early, decisive pharmacologic and digital intervention forestalls transition to chronic states, lowering future care costs. Telerehabilitation applications integrating AI-guided exercise have cut postoperative readmissions by 18% in community hospital pilots.

In contrast, sub-acute back pain-often tied to workplace injury-presents a preventative opportunity for employers deploying ergonomics programs. Wearable posture sensors that feed into machine-learning dashboards alert users and human-resources departments about risky movement patterns, curbing incidence rates. Other pain categories, such as neuropathic and radicular pain, rely heavily on neuromodulation; insurers are beginning to approve dorsal-root ganglion stimulation when conventional SCS fails, widening the total addressable population.

Imaging captured 33.40% of 2025 revenue and is climbing 8.3% per year as protocols mandate objective verification before high-cost interventions. MRI remains the gold standard to detect disc herniation and Modic changes, while low-dose CT fills triage roles in trauma units. AI-aided post-processing improves diagnostic speed; NEC's skeletal-pose engine raises detection accuracy for spondylolisthesis to 94%.

While clinical history and physical examination are entry points, payers increasingly demand imaging substantiation for reimbursement. Pain-score questionnaires, though essential for tracking, are now embedded in mobile apps, delivering real-time pain-intensity feeds to clinicians. Decision-support tools synthesize imaging and subjective metrics to flag candidates for minimally invasive ablation, trimming unnecessary surgical consults

Complete Report Scope:

• By Pain Type
  • Acute Pain
  • Sub-acute Low Back Pain
  • Chronic Back Pain
  • Other Pain Types
• By Diagnosis
  • Assessment of Pain Scores
  • Clinical History
  • Physical Examination
  • Imaging Guidelines
• By Therapy Modality
  • Pharmacologic
  • Neuromodulation
  • Regenerative
  • Minimally-Invasive Ablation
• By End User
  • Hospitals
  • Orthopaedic & Pain Clinics
  • Ambulatory Surgical Centres
  • Home-care Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained leadership with 39.70% of global revenue in 2025, helped by an installed base of more than 230,000 active spinal cord stimulators and favorable coding for closed-loop upgrades. FDA fast-track programs for breakthrough devices funnel innovations to market quickly, bolstering first-mover advantages for domestic manufacturers. Europe follows, aided by the Medical Device Regulation's emphasis on clinical evidence, which accelerates uptake of technologies demonstrating opioid-sparing benefits.

The Asia Pacific chronic lower back pain market will grow 8.53% yearly through 2031 as Japan's 22.5% adult pain prevalence forces systemic healthcare reforms. China's inclusion of ion-channel modulators in the National Reimbursement Drug List widens access to novel pharmacology, while Australia's early-adopter stance on neuromodulation guidelines positions it as a regional reference site. Investments in ambulatory surgery centers and physician training are lowering procedural backlogs across India and Southeast Asia.

South America and the Middle East & Africa collectively represent under 10% of current revenue but offer long-run upside given rising obesity rates and expanding private insurance coverage. Partnerships between Gulf-state hospitals and U.S. academic centers now include tele-mentoring for minimally invasive ablation, transferring skills without travel. Public-private initiatives in Brazil are piloting mobile MRI vans to deliver rural imaging services, showing early promise in shortening diagnostic delays.

1. Medtronic
2. Boston Scientific
3. Johnson & Johnson
4. Pfizer
5. Eli Lilly and Company
6. Abbott Laboratories
7. Nevro
8. Stryker
9. Merck
10. Vertebral Technologies, Inc.
11. Mesoblast Limited
12. SpineThera, Inc.
13. Stayble Therapeutics AB
14. Persica Pharmaceuticals
15. Pacira BioSciences
16. Kyphon (BD)
17. Grunenthal GmbH
18. Nektar Therapeutics
19. DePuy Synthes Spine
20. Teva Pharmaceutical Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rapid Uptake of Neuromodulation & SCS Implants
  • 4.2.2 Rising Prevalence of Obesity & Sedentary Lifestyles
  • 4.2.3 Growing Geriatric Population Susceptible to CLBP
  • 4.2.4 Expansion of Stem-Cell & Orthobiologic Trials
  • 4.2.5 AI-Driven Digital-Twin Models for Personalised Pain Therapy
  • 4.2.6 Value-Based Reimbursement Favouring Non-Opioid Solutions
• 4.3 Market Restraints
  • 4.3.1 High Upfront Cost of Advanced Neurostimulators
  • 4.3.2 Strict Opioid Prescribing & Reimbursement Clamp-Downs
  • 4.3.3 Data-Privacy Risks in Cloud-Programmed Stimulators
  • 4.3.4 Semiconductor Shortages Delaying Closed-Loop SCs Launches
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Pain Type
  • 5.1.1 Acute Pain
  • 5.1.2 Sub-acute Low Back Pain
  • 5.1.3 Chronic Back Pain
  • 5.1.4 Other Pain Types
• 5.2 By Diagnosis
  • 5.2.1 Assessment of Pain Scores
  • 5.2.2 Clinical History
  • 5.2.3 Physical Examination
  • 5.2.4 Imaging Guidelines
• 5.3 By Therapy Modality
  • 5.3.1 Pharmacologic
  • 5.3.2 Neuromodulation
  • 5.3.3 Regenerative
  • 5.3.4 Minimally-Invasive Ablation
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Orthopaedic & Pain Clinics
  • 5.4.3 Ambulatory Surgical Centres
  • 5.4.4 Home-care Settings
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Medtronic
  • 6.3.2 Boston Scientific Corporation
  • 6.3.3 Johnson & Johnson (DePuy Synthes)
  • 6.3.4 Pfizer Inc.
  • 6.3.5 Eli Lilly and Company
  • 6.3.6 Abbott Laboratories
  • 6.3.7 Nevro Corporation
  • 6.3.8 Stryker Corporation
  • 6.3.9 Merck & Co., Inc.
  • 6.3.10 Vertebral Technologies, Inc.
  • 6.3.11 Mesoblast Limited
  • 6.3.12 SpineThera, Inc.
  • 6.3.13 Stayble Therapeutics AB
  • 6.3.14 Persica Pharmaceuticals
  • 6.3.15 Pacira BioSciences, Inc.
  • 6.3.16 Kyphon (BD)
  • 6.3.17 Grunenthal GmbH
  • 6.3.18 Nektar Therapeutics
  • 6.3.19 DePuy Synthes Spine
  • 6.3.20 Teva Pharmaceutical Industries

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment